Catalytic Photooxygenation Demonstrates Therapeutic Efficacy in Transthyretin Amyloidosis
Mina Yamane1, Hiroki Umeda1, Moe Toyobe1
1Graduate School of Pharmaceutical Sciences, Synthetic Organic Chemistry Lab, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
Abstract:
The escalating global trend of aging populations has brought attention to the rising prevalence of late-onset amyloid disorders. Among them, amyloid transthyretin (ATTR) amyloidosis presents a growing area of unmet medical needs. While current treatment modalities have demonstrated efficacy in preventing or delaying amyloid generation, methodology to selectively modify and neutralize existing amyloid burdens remains inadequately addressed, leaving the fundamental irreversibility and hence the fatality of these conditions, a long-standing medical challenge. Here, we report the first demonstration of therapeutic efficacy in ATTR amyloidosis via dynamic control of ATTR aggregation and toxicity, enabled by small-molecule organophotocatalysis. Selective incorporation of hydrophilic oxygen atoms into the hydrophobic amyloid core reshapes the aggregation landscape, neutralizing proteotoxicity, and mitigating cellular damage. Additionally, this targeted covalent modification significantly reduces in vivo ROS levels, correlating with the observed therapeutic effects in Caenorhabditis elegans, the only experimental model replicating key clinical manifestations of the disease. Docking simulations elucidated the molecular basis of catalyst performance, providing the foundational blueprint for amyloid-neutralizing organophotocatalysis. Collectively, this study provides a scalable approach to overcoming a persistent barrier in amyloidosis therapy.
Insights
Researchers developed a novel small-molecule organophotocatalysis method to neutralize existing amyloid transthyretin (ATTR) burdens. This approach reshapes ATTR aggregation, reduces toxicity, and shows therapeutic effects in a disease model.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Gerontology
Background:
- Aging populations are increasing globally, leading to a rise in late-onset amyloid disorders.
- Amyloid transthyretin (ATTR) amyloidosis is a significant unmet medical need.
- Current treatments focus on preventing amyloid formation, not clearing existing amyloid burdens.
Purpose of the Study:
- To demonstrate the therapeutic efficacy of small-molecule organophotocatalysis in ATTR amyloidosis.
- To develop a method for dynamic control and neutralization of existing ATTR amyloid.
- To address the challenge of irreversibility and fatality in amyloidosis.
Main Methods:
- Small-molecule organophotocatalysis was employed to modify ATTR aggregates.
- Hydrophilic oxygen atoms were selectively incorporated into the hydrophobic amyloid core.
- Therapeutic effects were evaluated in *Caenorhabditis elegans* models.
- Docking simulations were used to elucidate the molecular mechanism.
Main Results:
- The organophotocatalysis approach reshaped the ATTR aggregation landscape.
- Proteotoxicity and cellular damage were neutralized.
- In vivo reactive oxygen species (ROS) levels were significantly reduced.
- Therapeutic effects were observed in a *C. elegans* model of ATTR amyloidosis.
Conclusions:
- Small-molecule organophotocatalysis offers a scalable approach to neutralize existing amyloid burdens.
- This method provides a potential therapeutic strategy for ATTR amyloidosis.
- The study lays the groundwork for developing amyloid-neutralizing organophotocatalysis.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...